PCSK9 and aortic valve stenosis: In a post hoc, exploratory analysis of the FOURIER trial of the PCSK9 inhibitor evolocumab, higher Lp(a), but not higher LDL-C, was associated with greater likelihood of new AS diagnoses or AS worsening over ∼2 years of follow-up.52